Oncolytic viruses as phenotyping agents for neoplasms

• US 7,306,902 B2
• Filed: 06/24/2003
• Issued: 12/11/2007
• Est. Priority Date: 06/28/2002
• Status: Expired due to Term

• Current Assignee: Oncolytics Biotech Incorporated
• Original Assignee: Oncolytics Biotech Incorporated
• Inventors: Coffey, Matthew C., Thompson, Bradley G.
• Primary Examiner(s): Campell; Bruce R.
• Assistant Examiner(s): LI, BAO Q
• Application Number:
  US10/602,024
• Publication Number:
  US 20040029112A1
• Time in Patent Office: 1,631 Days
• Field of Search: 435/264, 435/325, 435/42, 435/5, 435/2, 435/7.21
• US Class Current: 435/5
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: G01N 2333/14 Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus
• CPC Class Codes: G01N 33/574 for cancer
• CPC Class Codes: G01N 33/5748 involving oncogenic proteins
• CPC Class Codes: Y10S 435/975 Kit

Abstract

The present invention provides a method of diagnosing neoplasms having a particular phenotype by using oncolytic viruses that selectively replicate in neoplasms having the particular phenotype. For example, reovirus does not replicate in normal cells. However, reovirus selectively replicate in cells with an activated ras pathway, which leads to death of these cells. Therefore, a cell which becomes neoplastic due to, at least in part, elevated ras pathway activities can be diagnosed by its susceptibility to reovirus replication. This invention can further be applied, using other oncolytic viruses, to the diagnosis and/or treatment of other tumors, such as interferon-sensitive tumors, p53-deficient tumors and Rb-deficient tumors. Kits useful in the diagnosis or treatment disclosed herein are also provided.

Claims

1. A method of diagnosing a neoplasm in an animal by phenotype, comprising:

(a) providing a biological sample from the animal, wherein the sample comprises neoplastic cells with one or more unknown phenotypes;

(b) providing at least two oncolytic viruses, wherein each oncolytic virus selectively replicates in neoplastic cells having a known phenotype selected from the group consisting of ras pathway activation, interferon-resistance, p53-deficiency and Rb-deficiency; and

wherein each of the at least two oncolytic viruses replicates in neoplastic cells having a known different phenotype;

(c) contacting the neoplastic cells from the sample with each of the at least two oncolytic viruses under conditions which allow each oncolytic virus to selectively replicate in the neoplastic cells from the sample;

(d) determining if each of the oncolytic viruses selectively replicates in the neoplastic cells from the sample; and

(e) diagnosing a neoplasm in the animal as comprising cells of a known phenotype according to the ability of each of the oncolytic viruses to selectively replicate in the neoplastic cells from the sample.

2. The method of claim 1 wherein the animal is a mammal.

3. The method of claim 2 wherein the mammal is human.

4. The method of claim 1 wherein the at least two oncolytic viruses are selected from the group consisting of reoviruses, adenoviruses mutated in the VA1 region, vaccinia viruses mutated in the K3L and/or E3L region, parapoxvirus off viruses mutated in the OV20.0L gene, influenza viruses mutated in the NS-1 gene, herpes viruses mutated in the γ

₁34.5 gene, vesicular stomatitis virus, ONYX-015 virus and Delta24 virus.

5. The method of claim 4 wherein at least one of the oncolytic viruses is selected from the group consisting of reovirus, vesicular stomatitis virus, ONYX-015 virus and Delta24 virus.

6. The method of claim 5 wherein the reovirus is a mammalian reovirus.

7. The method of claim 6 wherein the mammalian reovirus is a serotype 3 reovirus.

8. The method of claim 7 wherein the serotype 3 reovirus is a Dearing strain reovirus.

9. The method of claim 5 wherein the reovirus is an avian reovirus.

10. The method of claim 1 wherein the animal has a neoplasm selected from the group consisting of lung cancer, prostate cancer, colorectal cancer, thyroid cancer, renal cancer, adrenal cancer, liver cancer, pancreatic cancer, breast cancer, hematopoietic cancer and central and peripheral nervous system cancer.